The ALLFTD Bibliography:
The links below contain citations for all articles linked to the ALLFTD, ARTFL, LEFFTDS, and 4RTNI grants for funding. This includes both directly related (using data from the grants) and indirectly related (e.g. investigator partially supported by the grants).
Click here to continue to the PubMed search results for ALLFTD, ARTFL, and LEFFTDS!
Click here to continue to the PubMed search results for 4RTNI!
Recent Publications:
Vandebergh, Marijne et al. “Gene specific effects on brain volume and cognition of TMEM106B in frontotemporal lobar degeneration.” medRxiv : the preprint server for health sciences 2024.04.05.24305253. 5 Apr. 2024, doi:10.1101/2024.04.05.24305253. Preprint.
Saloner, Rowan et al. “Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.” Research square rs.3.rs-4103685. 28 Mar. 2024, doi:10.21203/rs.3.rs-4103685/v1. Preprint.
Staffaroni, Adam M et al. “Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.” JAMA network open vol. 7,4 e244266. 1 Apr. 2024, doi:10.1001/jamanetworkopen.2024.4266
Lifestyle and FTD:
Asken, Breton M et al. “Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration.” Journal of neurology, neurosurgery, and psychiatryvol. 94,7 (2023): 541-549. doi:10.1136/jnnp-2022-330866
Casaletto, Kaitlin B et al. “Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers.” JAMA neurology vol. 80,1 (2023): 82-90. doi:10.1001/jamaneurol.2022.4178
Casaletto, K B et al. “Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.” Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 16,1 (2020): 91-105. doi:10.1002/alz.12001
Key Publications
Staffaroni, Adam M et al. “Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.” JAMA network open vol. 7,4 e244266. 1 Apr. 2024, doi:10.1001/jamanetworkopen.2024.4266
Staffaroni, Adam M et al. “Temporal order of clinical and biomarker changes in familial frontotemporal dementia.” Nature medicine vol. 28,10 (2022): 2194-2206. doi:10.1038/s41591-022-01942-9
Gendron, Tania F et al. “Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.” Cell reports. Medicinevol. 3,4 100607. 19 Apr. 2022, doi:10.1016/j.xcrm.2022.100607
Barker, Megan S et al. “Proposed research criteria for prodromal behavioural variant frontotemporal dementia.” Brain : a journal of neurology vol. 145,3 (2022): 1079-1097. doi:10.1093/brain/awab365
Boxer, Adam L et al. “New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.” Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 16,1 (2020): 131-143. doi:10.1016/j.jalz.2019.06.4956
Casaletto, K B et al. “Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.” Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 16,1 (2020): 91-105. doi:10.1002/alz.12001
Moore, K. M. et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology 19(2):145-156. doi: 10.1016/S1474-4422(19)30394-1. (2020).
Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine 26, 387-397, doi:10.1038/s41591-020-0762-2 (2020).